RxDoctor Payments Data

Peter Nonack, MD

Internal Medicine · Media, PANPI 1225060502

Payments from drug & device makers

$291in general payments, 2019–2025

Across 18 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$128
  • Novo Nordisk$77
  • Lilly USA, LLC$27
  • Sanofi Pasteur Inc.$17
  • GSK$17
  • AstraZeneca$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen7$128
Novo Nordisk5$77
Lilly USA, LLC2$27
Sanofi Pasteur Inc.1$17
GSK1$17
AstraZeneca1$13
Pfizer1$12

How this compares

$291 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,704
Medicare patients
512
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$110,877
FarxigaDapagliflozin Propanediol93$77,202
JanuviaSitagliptin Phosphate57$67,081
MounjaroTirzepatide54$66,220
OzempicSemaglutide21$34,596
XareltoRivaroxaban25$31,408
TrulicityDulaglutide18$18,797
Spiriva HandihalerTiotropium Bromide20$12,464
Atorvastatin Calcium586$6,349
Arnuity ElliptaFluticasone Furoate21$6,226
Venlafaxine Hcl ErVenlafaxine Hcl41$5,268
BrilintaTicagrelor11$4,881
SynthroidLevothyroxine Sodium54$4,133
Simvastatin403$3,787
Losartan Potassium331$3,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$110,877137 claims
Lilly USA, LLCMounjaro, Trulicity$27$85,01772 claims
AstraZenecaFarxiga, Brilinta$13$82,083104 claims
Novo NordiskOzempic$77$34,59621 claims
GSKArnuity Ellipta$17$6,22621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →